SCYNEXIS, Inc. Enters into Worldwide Agreement with Waterstone Pharmaceutical for the 

                        Development and Commercialization of SCY-635 for Viral Diseases



Research Triangle Park, N.C. (October 30, 2014) – SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that they 

have entered into a license agreement granting Waterstone Pharmaceutical (HK Limited), an international 

pharmaceutical company with its main operations in China, exclusive worldwide rights to develop and commercialize 

SCY-635 for the treatment of viral diseases in humans.


“The transitioning of SCY-635 to Waterstone allows us to focus on the development of our novel oral and IV product 

candidate, SCY-078 for the treatment of invasive fungal infections, which is entering a Phase 2 clinical trial this quarter,

” said Yves J. Ribeill, Ph.D., President and Chief Executive Officer of SCYNEXIS.


“SCY-635 is a cyclophilin inhibitor which has shown promise in treating viral infections through its selective targeting of a 

host protein” said Faming Zhang, Ph.D., Chief Executive Officer of Waterstone. “This promising technology developed by 

SCYNEXIS has the potential to bring new hope for improved therapies to patients suffering from chronic viral infections.”


Under the terms of the agreement, Waterstone has worldwide development and commercialization rights to SCY-635 for 

the treatment of human viral diseases, as well as the option to license two additional cyclophilin inhibitors.  SCYNEXIS will 

receive an upfront payment and is entitled to certain commercialization milestones and royalties.



SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel 

anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, 

SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal 

infections in humans. For more information, visit


About Waterstone

Waterstone is a pharmaceutical company focused in discovery, development and commercialization of innovative 

drugs for the treatment of liver and gastrointestinal diseases. With venture capital investments from internationally 

well-known firms such as BAR Capital, CID Group, Orbimed, and Acorn Camps, the company has established fully 

integrated capabilities from R&D, API & Finished Drug Product manufacturing to sales/marketing. The company has 

a strong management team with cross-border experience and advisors with expertise in drug discovery, regulatory, 

and GMP manufacturing. For more information, visit


About SCY-635

SCY-635 is a cyclophilin inhibitor being developed as a novel, orally available agent for the treatment of viral diseases.  

In a Phase 2a study conducted in difficult to treat Hepatitis C (HCV) patients, SCY-635 modulated patients’ immune 

response by making PEG-interferon refractory patients sensitive to anti-viral activity of PEG-interferon. Results of the 

study were presented at AASLD in Boston in 2012. SCY-635 has also shown in vitro activity against other viral 

diseases including Hepatitis B Virus (HBV).


Forward Looking Statement

Statements contained in this press release regarding matters that are not historical facts are “forward-looking 

statement” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements 

are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such 

forward-looking statements. Risks are described more fully in SCYNEXIS’s filings with the Securities and Exchange 

Commission, including without limitation its most recent Quarterly Report on Form 10-Q and other documents 

subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements 

contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no 

obligation to update such statements to reflect events that occur or circumstances that exist after the date on 

which they were made.


Media Relations

Heather Savelle

MacDougall Biomedical Communications

Tel: 781-235-3060


Investor Relations

Jillian Connell

The Trout Group LLC

Tel: 646-378-2956



SCYNEXIS, Inc. Contact

Chuck Osborne

Chief Financial Officer

Tel: 919-544-8600



Waterstone Pharmaceuticals Contact

Tina Jia
Tel: +86 27 8664 4715


Company Profile
Management Team
Vision & Mission
Highly Potent ADC Drugs
Company News
Media Reports
Location & massage